scholarly journals Clinical research in homeopathy: asking the right questions

2021 ◽  
Vol 11 (40) ◽  
pp. 131-131
Author(s):  
Robert T Mathie

Identifying the ‘right’ clinical research questions in homeopathic medicine requires that the targets for that research are clearly and optimally defined. The definition of such targets depends, in turn, on a full and clear understanding of the current research evidence base. Moreover, it is crucial to retain a scientifically objective and consistent approach that is not distracted by extremes of opinion on either side of the debate about the research evidence in homeopathy. The main focus logically must be on randomised controlled trials (RCTs) because, despite reservations about their application to homeopathy research in the past, they are the only available way to prove cause and effect of an intervention. Many commentators, however, have failed to distinguish between the findings of placebo- and other-than-placebo (OTP)- controlled trials, while the individualised style of the normal homeopathic intervention and the main effects anticipated from that intervention have not always been properly reflected. Thus, the interpretation of findings in terms of ‘efficacy’ or ‘effectiveness’ of the intervention is often unclear. Our method of ‘vote counting’ the results of RCTs in homeopathy has enabled a clear categorisation of the research evidence, together with an opportunity to reflect condition-specific findings. That approach is not without flaws, however, and a more appropriate and sophisticated systematic review (SR) of the RCT evidence would be additionally helpful. Previous SRs of RCTs in homeopathy have typically failed to provide clear conclusions about the effectiveness of homeopathy as a system of medicine or about the efficacy of particular medicines. This is largely the result of a failure to distinguish: individualised from non-individualised homeopathy; treatment from prophylaxis; and internal validity (risk of bias) from model validity (‘state of the art’ practice and relevant outcome measures). And SRs have paid little attention to the potency of the homeopathic medicines used, to reviewing OTP-controlled RCTs, or to distinguishing between research published in the peer-reviewed and the non-peer-reviewed literature. A clearer and more complete awareness of the current RCT evidence will emerge from the above SR programme, which is now in progress. Importantly, the attributes of homeopathy and study design that it addresses can be fully reflected in answering the key questions that are then applied to new RCTs in homeopathy.

Trauma ◽  
2020 ◽  
Vol 22 (3) ◽  
pp. 229-232
Author(s):  
Aidan Brown ◽  
Adam Low

Methods of extrication and spinal immobilisation following trauma remains controversial. There is a consensus shift towards encouraging patients to self-extricate from vehicles after collisions and reduced use of hard cervical collars. Difficulties in conducting randomised controlled trials in this area means that case reports are important in adding to the existing evidence base. This case of an 81-year-old female polytrauma patient suggests that self-extrication, and not using hard cervical collars is safe practice, even in the context of significant multi-level spinal injuries.


BMJ Open ◽  
2019 ◽  
Vol 9 (10) ◽  
pp. e031151 ◽  
Author(s):  
Karin A Wasmann ◽  
Pieta Wijsman ◽  
Susan van Dieren ◽  
Willem Bemelman ◽  
Christianne Buskens

ObjectiveRandomised controlled trials (RCT) are the gold standard to provide unbiased data. However, when patients have a treatment preference, randomisation may influence participation and outcomes (eg, external and internal validity). The aim of this study was to assess the influence of patients’ preference in RCTs by analysing partially randomised patient preference trials (RPPT); an RCT and preference cohort combined.DesignSystematic review and meta-analyses.Data sourcesMEDLINE, Embase, PsycINFO and the Cochrane Library.Eligibility criteria for selecting studiesRPPTs published between January 2005 and October 2018 reporting on allocation of patients to randomised and preference cohorts were included.Data extraction and synthesisTwo independent reviewers extracted data. The main outcomes were the difference in external validity (participation and baseline characteristics) and internal validity (lost to follow-up, crossover and the primary outcome) between the randomised and the preference cohort within each RPPT, compared in a meta-regression using a Wald test. Risk of bias was not assessed, as no quality assessment for RPPTs has yet been developed.ResultsIn total, 117 of 3734 identified articles met screening criteria and 44 were eligible (24 873 patients). The participation rate in RPPTs was >95% in 14 trials (range: 48%–100%) and the randomisation refusal rate was >50% in 26 trials (range: 19%–99%). Higher education, female, older age, race and prior experience with one treatment arm were characteristics of patients declining randomisation. The lost to follow-up and cross-over rate were significantly higher in the randomised cohort compared with the preference cohort. Following the meta-analysis, the reported primary outcomes were comparable between both cohorts of the RPPTs, mean difference 0.093 (95% CI −0.178 to 0.364, p=0.502).ConclusionsPatients’ preference led to a substantial proportion of a specific patient group refusing randomisation, while it did not influence the primary outcome within an RPPT. Therefore, RPPTs could increase external validity without compromising the internal validity compared with RCTs.PROSPERO registration numberCRD42019094438.


2010 ◽  
Vol 196 (6) ◽  
pp. 434-439 ◽  
Author(s):  
Nicolas A. Crossley ◽  
Miguel Constante ◽  
Philip McGuire ◽  
Paddy Power

BackgroundThere is an ongoing debate about the use of atypical antipsychotics as a first-line treatment for first-episode psychosis.AimsTo examine the evidence base for this recommendation.MethodMeta-analyses of randomised controlled trials in the early phase of psychosis, looking at long-term discontinuation rates, short-term symptom changes, weight gain and extrapyramidal side-effects. Trials were identified using a combination of electronic (Cochrane Central, EMBASE, MEDLINE and PsycINFO) and manual searches.ResultsFifteen randomised controlled trials with a total of 2522 participants were included. No significant differences between atypical and typical drugs were found for discontinuation rates (odds ratio (OR) = 0.7, 95% CI 0.4 to 1.2) or effect on symptoms (standardised mean difference (SMD) = –0.1, 95% CI –0.2 to 0.02). Participants on atypical antipsychotics gained 2.1 kg (95% CI 0.1 to 4.1) more weight than those on typicals, whereas those on typicals experienced more extrapyramidal side-effects (SMD = –0.4, 95% CI –0.5 to –0.2).ConclusionsThere was no evidence for differences in efficacy between atypical and typical antipsychotics, but there was a clear difference in the side-effect profile.


2017 ◽  
Vol 26 (1) ◽  
pp. 38-40 ◽  
Author(s):  
John Little

Objectives: To explore a contradiction between evidence suggesting community treatment order (CTO) ineffectiveness and clinical experience. Conclusions: The literature pertaining to CTOs actually provides an evidence base for both positions. The headline that three randomised controlled trials and subsequent meta-analyses fail to demonstrate significant differences between groups reflects selection bias. A case may still be made for CTOs.


Sign in / Sign up

Export Citation Format

Share Document